It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HSIC’s FA Score shows that 1 FA rating(s) are green whileOMI’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HSIC’s TA Score shows that 3 TA indicator(s) are bullish while OMI’s TA Score has 2 bullish TA indicator(s).
HSIC (@Medical Distributors) experienced а +1.12% price change this week, while OMI (@Medical Distributors) price change was -4.96% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was -4.08%. For the same industry, the average monthly price growth was -5.78%, and the average quarterly price growth was -14.46%.
HSIC is expected to report earnings on Feb 12, 2025.
OMI is expected to report earnings on Feb 19, 2025.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
HSIC | OMI | HSIC / OMI | |
Capitalization | 9.71B | 2.11B | 461% |
EBITDA | 877M | 391M | 224% |
Gain YTD | -9.180 | -36.378 | 25% |
P/E Ratio | 23.50 | 64.10 | 37% |
Revenue | 12.3B | 10.3B | 119% |
Total Cash | 171M | 243M | 70% |
Total Debt | 2.74B | 2.32B | 118% |
HSIC | OMI | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 83 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 74 | 82 | |
SMR RATING 1..100 | 68 | 88 | |
PRICE GROWTH RATING 1..100 | 58 | 85 | |
P/E GROWTH RATING 1..100 | 28 | 3 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OMI's Valuation (67) in the Medical Distributors industry is in the same range as HSIC (77). This means that OMI’s stock grew similarly to HSIC’s over the last 12 months.
HSIC's Profit vs Risk Rating (74) in the Medical Distributors industry is in the same range as OMI (82). This means that HSIC’s stock grew similarly to OMI’s over the last 12 months.
HSIC's SMR Rating (68) in the Medical Distributors industry is in the same range as OMI (88). This means that HSIC’s stock grew similarly to OMI’s over the last 12 months.
HSIC's Price Growth Rating (58) in the Medical Distributors industry is in the same range as OMI (85). This means that HSIC’s stock grew similarly to OMI’s over the last 12 months.
OMI's P/E Growth Rating (3) in the Medical Distributors industry is in the same range as HSIC (28). This means that OMI’s stock grew similarly to HSIC’s over the last 12 months.
HSIC | OMI | |
---|---|---|
RSI ODDS (%) | N/A | N/A |
Stochastic ODDS (%) | 3 days ago59% | 3 days ago79% |
Momentum ODDS (%) | 3 days ago65% | 3 days ago82% |
MACD ODDS (%) | 3 days ago58% | 3 days ago84% |
TrendWeek ODDS (%) | 3 days ago56% | 3 days ago80% |
TrendMonth ODDS (%) | 3 days ago54% | 3 days ago79% |
Advances ODDS (%) | 14 days ago55% | 7 days ago74% |
Declines ODDS (%) | 10 days ago55% | 3 days ago81% |
BollingerBands ODDS (%) | 3 days ago59% | 3 days ago79% |
Aroon ODDS (%) | N/A | 3 days ago77% |
A.I.dvisor indicates that over the last year, HSIC has been loosely correlated with PDCO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if HSIC jumps, then PDCO could also see price increases.
Ticker / NAME | Correlation To HSIC | 1D Price Change % | ||
---|---|---|---|---|
HSIC | 100% | +3.34% | ||
PDCO - HSIC | 54% Loosely correlated | +0.92% | ||
OMI - HSIC | 24% Poorly correlated | -0.08% | ||
CAH - HSIC | 20% Poorly correlated | -2.07% | ||
COR - HSIC | 18% Poorly correlated | -1.08% | ||
ZYXI - HSIC | 16% Poorly correlated | -3.58% | ||
More |
A.I.dvisor indicates that over the last year, OMI has been loosely correlated with ZYXI. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if OMI jumps, then ZYXI could also see price increases.
Ticker / NAME | Correlation To OMI | 1D Price Change % | ||
---|---|---|---|---|
OMI | 100% | -0.08% | ||
ZYXI - OMI | 36% Loosely correlated | -3.58% | ||
CAH - OMI | 31% Poorly correlated | -2.07% | ||
HSIC - OMI | 24% Poorly correlated | +3.34% | ||
PDCO - OMI | 17% Poorly correlated | +0.92% | ||
COR - OMI | 12% Poorly correlated | -1.08% | ||
More |